Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
CT/MRI Co-Registration Prostate Cancer
This study is ongoing, but not recruiting participants.
Sponsors and Collaborators: University Health Network, Toronto
Princess Margaret Hospital, Canada
Information provided by: University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT00252460
  Purpose

The target volume in prostate cancer radiotherapy typically consists of the entire prostate gland which is localized by contours drawn on axial computed tomography (CT) radiation planning images. Compared with CT, magnetic resonance (MR) can provide better definition of the prostate gland with respect to the surrounding tissues and the use of multi-plannar reconstruction avoids the problem of partial volume averaging inherent in CT. CT has been shown to significantly overestimate the volume of the gland using the MR-defined prostate volume as the gold standard. Co-registration of MR and CT datasets, matched on fixed bony landmarks, has enabled radiation planning using a MR-defined clinical target volumes, combined with CT-based electron density information necessary for radiation treatment planning.

Rationale and Hypothesis:

Co-registration may allow better delineation of tumour volumes in prostate cancer. This investigation is a fesibility study designed to evaluate and optimize imaging parameters and co-registration techniques for CT planning and MRI Simulator.


Condition Intervention Phase
Prostatic Neoplasm
Device: Computed Tomography Scan and Magnetic Resonance Imaging
Phase I

MedlinePlus related topics: CT Scans Cancer MRI Scans Nuclear Scans Prostate Cancer
U.S. FDA Resources
Study Type: Observational
Study Design: Screening, Cross-Sectional, Defined Population, Prospective Study
Official Title: Evaluation of Planning Computed Tomography Scan and Magnetic Resonance Imaging Simulator Scan Co-Registration for Delineation of Gross Tumour Volume in Radiotherapy Treatment of Localized Prostate Cancer

Further study details as provided by University Health Network, Toronto:

Estimated Enrollment: 30
Study Start Date: November 2003
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological confirmation of Prostate Adenocarcinoma
  • Undergoing RT with fiducial markers, IMRT or Escalated Dose Conformal RT

Exclusion Criteria:

  • Contraindication for MRI
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00252460

Locations
Canada, Ontario
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
University Health Network, Toronto
Princess Margaret Hospital, Canada
Investigators
Principal Investigator: Andrew Bayley, MD Princess Margaret Hospital, Canada
  More Information

Study ID Numbers: UHN REB 03-0601-CE
Study First Received: November 9, 2005
Last Updated: November 9, 2005
ClinicalTrials.gov Identifier: NCT00252460  
Health Authority: Canada: Ethics Review Committee

Study placed in the following topic categories:
Prostatic Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 14, 2009